As an epidemiologist, I develop large databases of gastrointestinal (GI) motility tests and procedures with millions of data points to infer hypotheses that will be used in drug and device development in gastroenterology in conjunction with work done by my colleagues, Mark Pimentel, MD, and Ruchi Mathur, MD."
- Irritable Bowel Syndrome - Studying disturbances in large intestines (25 to 45 million Americans—of which about 66 percent are women—suffer from IBS)
- Microbiome - Uncovering the genetic material of bacteria, fungi, archaea and viruses affecting the GI tract
- Small Intestinal Bacterial Overgrowth - Looking for drug alternatives to treat excessive bacteria in the small intestine that inhibit digestion and absorption
- Biomarkers - Developing therapeutic interventions to combat symptoms and causes of GI motility disorders and IBD
- Alternatives to Antibiotics - Finding new treatments independent of antibiotics
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Rezaie Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Rezaie A, Park SC, Morales W, Marsh E, Lembo A, Kim JH, Weitsman S, Chua KS, Barlow GM, Pimentel M.
Dig Dis Sci. 2017;62(6):1480-1485.
Rezaie A, Iriana S, Pimentel M, Murrell Z, Fleshner P, Zaghiyan K.
Colorectal Dis. 2017;19(5):468-475.
Gu P, Huang B, Rezaie A.